Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma | Haematologica
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
Daratumumab and hyaluronidase-fihj (Darzalex Faspro) Drug Info
Box plot of DARA maximum C trough for nonresponders and responders... | Download Scientific Diagram
Samer Al Hadidi, MD,MS,FACP on X: "#ASH21 #mmsm Oral sessions on trials @ASH_hematology Talquetamab + Daratumumab ➡️around half pts had previous BCMA therapy ➡️F/U only ~4 mo ➡️ ORR of up to
Darzalex Faspro® (daratumumab and hyaluronidase-fihj)
POMALYST® (pomalidomide) APOLLO Clinical Trial Efficacy & Safety Data
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS | Blood Cancer Journal
POMALYST® (pomalidomide) APOLLO Clinical Trial Efficacy & Safety Data
Subcutaneous Daratumumab for Multiple Myeloma: Applying the Lessons from Clinical Trials to Clinical Practice - Journal of Oncology Navigation & Survivorship
Courtenay Thompson: Experience with Dara FasPro - HealthTree for Multiple Myeloma
Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma | International Journal of Hematology
Dosing and administration schema for subcutaneous daratumumab. C1D1,... | Download Scientific Diagram
Understanding Darzalex Faspro - YouTube
Trimm 2 Study - Multiple Myeloma Clinical Trials
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
DARZALEX® AND DARZALEX FASPRO™ SPECIALTY DISTRIBUTORS